A model of CRC was chosen since it has been shown that ILCs support CRC growth via IL-22 and we wondered whether within this model, PD-1 can increase Tbet+NK1.1− ILCs with a type 1 phenotype. The gene discussed is IL22; the disease is colorectal carcinoma.